{
  "guid": "a3c3d0dc-2862-4ef7-865e-e54582cadce0",
  "title": "The State of the Pandemic",
  "description": "<p>The coronavirus seems to be in retreat in the United States, with the number of cases across the country down about 25 percent compared with a couple of weeks ago. Hospitalizations and deaths are also falling.</p><p>So, what stage are we in with the pandemic? And how will developments such as a new antiviral treatment and the availability of booster shots affect things?</p><p>Guest: <a href=\"https://www.nytimes.com/by/apoorva-mandavilli?smid=pc-thedail\">Apoorva Mandavilli</a>, a science and global health reporter for The New York Times. </p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li>The authorization for booster shots<a href=\"https://www.nytimes.com/2021/09/24/us/politics/biden-booster-shots-moderna-johnson-johnson.html\"> applies to groups of people in the United States fully vaccinated with the Pfizer vaccine</a>, but about 45 percent of the country’s fully inoculated people received Moderna or Johnson & Johnson doses.</li><li>Merck said it would seek authorization for molnupiravir, an antiviral pill that the company says is effective against Covid. Experts said such treatments could be<a href=\"https://www.nytimes.com/2021/10/01/business/covid-antiviral-pill-merck.html\"> a powerful tool against the virus</a>.</li><li>Despite<a href=\"https://www.nytimes.com/2021/10/06/us/covid-delta-us-surge-vaccines.html\"> a fall in new cases, hospitalizations and deaths</a>, public health officials said the pandemic remained a potent threat.</li></ul><p>For more information on today’s episode, visit </p><p><a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a></p><p>. Transcripts of each episode will be made available by the next workday.</p>\n",
  "pubDate": "Thu, 7 Oct 2021 09:45:00 +0000",
  "author": "thedaily@nytimes.com (The New York Times)",
  "link": "https://www.nytimes.com/the-daily",
  "content:encoded": "<p>The coronavirus seems to be in retreat in the United States, with the number of cases across the country down about 25 percent compared with a couple of weeks ago. Hospitalizations and deaths are also falling.</p><p>So, what stage are we in with the pandemic? And how will developments such as a new antiviral treatment and the availability of booster shots affect things?</p><p>Guest: <a href=\"https://www.nytimes.com/by/apoorva-mandavilli?smid=pc-thedail\">Apoorva Mandavilli</a>, a science and global health reporter for The New York Times. </p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li>The authorization for booster shots<a href=\"https://www.nytimes.com/2021/09/24/us/politics/biden-booster-shots-moderna-johnson-johnson.html\"> applies to groups of people in the United States fully vaccinated with the Pfizer vaccine</a>, but about 45 percent of the country’s fully inoculated people received Moderna or Johnson & Johnson doses.</li><li>Merck said it would seek authorization for molnupiravir, an antiviral pill that the company says is effective against Covid. Experts said such treatments could be<a href=\"https://www.nytimes.com/2021/10/01/business/covid-antiviral-pill-merck.html\"> a powerful tool against the virus</a>.</li><li>Despite<a href=\"https://www.nytimes.com/2021/10/06/us/covid-delta-us-surge-vaccines.html\"> a fall in new cases, hospitalizations and deaths</a>, public health officials said the pandemic remained a potent threat.</li></ul><p>For more information on today’s episode, visit </p><p><a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a></p><p>. Transcripts of each episode will be made available by the next workday.</p>\n",
  "enclosure": "",
  "itunes:title": "The State of the Pandemic",
  "itunes:author": "The New York Times",
  "itunes:duration": "00:19:21",
  "itunes:summary": "The coronavirus seems to be in retreat in the United States, with the number of cases across the country down about 25 percent compared with a couple of weeks ago. Hospitalizations and deaths are also falling.\n\nSo, what stage are we in with the pandemic? And how will developments such as a new antiviral treatment and the availability of booster shots affect things?\n\nGuest: Apoorva Mandavilli, a science and global health reporter for The New York Times.",
  "itunes:subtitle": "The coronavirus seems to be in retreat in the United States, with the number of cases across the country down about 25 percent compared with a couple of weeks ago. Hospitalizations and deaths are also falling.\n\nSo, what stage are we in with the pandemic? And how will developments such as a new antiviral treatment and the availability of booster shots affect things?\n\nGuest: Apoorva Mandavilli, a science and global health reporter for The New York Times.",
  "itunes:explicit": "no",
  "itunes:episodeType": "full"
}